936 related articles for article (PubMed ID: 16534009)
1. The Seattle Heart Failure Model: prediction of survival in heart failure.
Levy WC; Mozaffarian D; Linker DT; Sutradhar SC; Anker SD; Cropp AB; Anand I; Maggioni A; Burton P; Sullivan MD; Pitt B; Poole-Wilson PA; Mann DL; Packer M
Circulation; 2006 Mar; 113(11):1424-33. PubMed ID: 16534009
[TBL] [Abstract][Full Text] [Related]
2. Improving outcomes with long-term "destination" therapy using left ventricular assist devices.
Long JW; Healy AH; Rasmusson BY; Cowley CG; Nelson KE; Kfoury AG; Clayson SE; Reid BB; Moore SA; Blank DU; Renlund DG
J Thorac Cardiovasc Surg; 2008 Jun; 135(6):1353-60; discussion 1360-1. PubMed ID: 18544385
[TBL] [Abstract][Full Text] [Related]
3. Prediction of mode of death in heart failure: the Seattle Heart Failure Model.
Mozaffarian D; Anker SD; Anand I; Linker DT; Sullivan MD; Cleland JG; Carson PE; Maggioni AP; Mann DL; Pitt B; Poole-Wilson PA; Levy WC
Circulation; 2007 Jul; 116(4):392-8. PubMed ID: 17620506
[TBL] [Abstract][Full Text] [Related]
4. Validation of the Seattle Heart Failure Model in a community-based heart failure population and enhancement by adding B-type natriuretic peptide.
May HT; Horne BD; Levy WC; Kfoury AG; Rasmusson KD; Linker DT; Mozaffarian D; Anderson JL; Renlund DG
Am J Cardiol; 2007 Aug; 100(4):697-700. PubMed ID: 17697831
[TBL] [Abstract][Full Text] [Related]
5. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure).
Stevenson LW; Miller LW; Desvigne-Nickens P; Ascheim DD; Parides MK; Renlund DG; Oren RM; Krueger SK; Costanzo MR; Wann LS; Levitan RG; Mancini D;
Circulation; 2004 Aug; 110(8):975-81. PubMed ID: 15313942
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection.
Lietz K; Long JW; Kfoury AG; Slaughter MS; Silver MA; Milano CA; Rogers JG; Naka Y; Mancini D; Miller LW
Circulation; 2007 Jul; 116(5):497-505. PubMed ID: 17638928
[TBL] [Abstract][Full Text] [Related]
7. Left ventricular assist devices as destination therapy: a new look at survival.
Park SJ; Tector A; Piccioni W; Raines E; Gelijns A; Moskowitz A; Rose E; Holman W; Furukawa S; Frazier OH; Dembitsky W
J Thorac Cardiovasc Surg; 2005 Jan; 129(1):9-17. PubMed ID: 15632819
[TBL] [Abstract][Full Text] [Related]
8. A novel prognostic index to determine the impact of cardiac conditions and co-morbidities on one-year outcome in patients with heart failure.
Senni M; Santilli G; Parrella P; De Maria R; Alari G; Berzuini C; Scuri M; Filippi A; Migliori M; Minetti B; Ferrazzi P; Gavazzi A
Am J Cardiol; 2006 Oct; 98(8):1076-82. PubMed ID: 17027575
[TBL] [Abstract][Full Text] [Related]
9. Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy.
John R; Kamdar F; Liao K; Colvin-Adams M; Boyle A; Joyce L
Ann Thorac Surg; 2008 Oct; 86(4):1227-34; discussion 1234-5. PubMed ID: 18805167
[TBL] [Abstract][Full Text] [Related]
10. Heart failure survival score continues to predict clinical outcomes in patients with heart failure receiving beta-blockers.
Koelling TM; Joseph S; Aaronson KD
J Heart Lung Transplant; 2004 Dec; 23(12):1414-22. PubMed ID: 15607672
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of risk indices in continuous-flow left ventricular assist device patients.
Schaffer JM; Allen JG; Weiss ES; Patel ND; Russell SD; Shah AS; Conte JV
Ann Thorac Surg; 2009 Dec; 88(6):1889-96. PubMed ID: 19932256
[TBL] [Abstract][Full Text] [Related]
12. The Munich score: a clinical index to predict survival in ambulatory patients with chronic heart failure in the era of new medical therapies.
Stempfle HU; Alt A; Stief J; Siebert U
J Heart Lung Transplant; 2008 Feb; 27(2):222-8. PubMed ID: 18267231
[TBL] [Abstract][Full Text] [Related]
13. Model for end-stage liver disease score predicts adverse events related to ventricular assist device therapy.
Bonde P; Ku NC; Genovese EA; Bermudez CA; Bhama JK; Ciarleglio MM; Cong X; Teuteberg JJ; Kormos RL
Ann Thorac Surg; 2012 May; 93(5):1541-7; discussion 1547-8. PubMed ID: 22480391
[TBL] [Abstract][Full Text] [Related]
14. Optimal medical therapy is superior to transplantation for the treatment of class I, II, and III heart failure: a decision analytic approach.
Freudenberger RS; Kim J; Tawfik I; Sonnenberg FA
Circulation; 2006 Jul; 114(1 Suppl):I62-6. PubMed ID: 16820647
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of medical therapy for the reduction of heart failure events in patients with implanted cardioverter defibrillators.
Pietrasik G; Goldenberg I; McNitt S; Polonsky B; Moss AJ; Zareba W
J Cardiovasc Electrophysiol; 2009 Apr; 20(4):395-400. PubMed ID: 19017351
[TBL] [Abstract][Full Text] [Related]
16. Comparison of observed survival after ventricular assist device placement versus predicted survival without assist device using the Seattle heart failure model.
Pamboukian SV; Tallaj JA; Brown RN; Nielsen T; George JF; Kirklin JK; Holman WL; Levy WC
ASAIO J; 2012; 58(2):93-7. PubMed ID: 22370679
[TBL] [Abstract][Full Text] [Related]
17. Trial-generated profiles for implantation of electrical devices in outpatients with heart failure: real-world prevalence and 1-year outcome.
Boriani G; Rapezzi C; Diemberger I; Gonzini L; Gorini M; Lucci D; Sinagra G; Cooke RM; Di Pasquale G; Tavazzi L; Maggioni AP
J Eval Clin Pract; 2010 Feb; 16(1):82-91. PubMed ID: 19874436
[TBL] [Abstract][Full Text] [Related]
18. Long-term survival in patients treated with cardiac resynchronization therapy: a 3-year follow-up study from the InSync/InSync ICD Italian Registry.
Gasparini M; Lunati M; Santini M; Tritto M; Curnis A; Bocchiardo M; Vincenti A; Pistis G; Valsecchi S; Denaro A;
Pacing Clin Electrophysiol; 2006 Dec; 29 Suppl 2():S2-10. PubMed ID: 17169128
[TBL] [Abstract][Full Text] [Related]
19. Validation of mortality risk stratification models for cardiovascular disease.
Nakayama M; Osaki S; Shimokawa H
Am J Cardiol; 2011 Aug; 108(3):391-6. PubMed ID: 21600539
[TBL] [Abstract][Full Text] [Related]
20. Can the Seattle heart failure model be used to risk-stratify heart failure patients for potential left ventricular assist device therapy?
Levy WC; Mozaffarian D; Linker DT; Farrar DJ; Miller LW;
J Heart Lung Transplant; 2009 Mar; 28(3):231-6. PubMed ID: 19285613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
